Literature DB >> 35982197

Favourable collaterals according to the Careggi Collateral Score grading system in patients treated with thrombectomy for stroke with middle cerebral artery occlusion.

Giulia Sajeva1, Raffaele Augelli2, Manuel Cappellari3, Cecilia Zivelonghi1, Mauro Plebani2, Nicolò Mandruzzato2, Salvatore Mangiafico4.   

Abstract

The ability of the current grading systems to predict optimal outcomes in stroke patients with favourable collaterals remains unexplored. We evaluated differences in the performance of grading systems between Careggi Collateral Score and ASITN/SIR collateral score to predict clinical and radiological outcomes in stroke patients with favourable collaterals who underwent thrombectomy. We included stroke patients receiving thrombectomy within 360 min after symptom onset with MCA occlusion and favourable collaterals (i.e., without poor collaterals) defined by ASITN/SIR collateral score between 2 and 4. Using ordinal regression, we estimated the association of each CCS and ASITN/SIR grade with mRS shift (0-6) at 3 months, NIHSS score (0-42) and ASPECT score (10-0) at baseline, TICI score (3-0), infarct growth, cerebral bleeding, and cerebral edema grading at 24 h by calculating the odds ratios (ORs) with two-sided 95% confidence intervals after adjustment for predefined variables. Using the best collateral grade (CCS = 4) as reference, ORs of the CCS grades were associated in the direction of unfavourable outcome on 3-month mRS shift (2.325 for CCS = 3; 5.092 for CCS = 2), in the direction of more severe baseline NIHSS score (5.434 for CCS = 3; 16.041 for CCS = 2), 24-h infarct growth (2.659 for CCS = 3; 8.288 for CCS = 4) and 24-h cerebral edema (1.057 for CCS = 3; 5.374 for CCS = 2) shift. ORs of the ASITN/SIR grades were associated in the direction of more severe baseline NIHSS score (4.332 for ASITN/SIR = 3; 16.960 for ASITN/SIR = 2) and 24-h infarct growth (2.138 for ASITN/SIR = 3; 7.490 for ASITN/SIR = 2) shift. The AUC ROC of CCS and ASITN/SIR for predicting 3-month mRS score 0-1 were 0.681 (95% CI: 0.562-0.799; p = 0.009) and 0.599 (95% CI: 0.466-0.73; p = 0.156), respectively. CCS = 4 and ASITN/SIR ≥ 3 were the optimal cut-offs to predict 3-month mRS score 0-1, respectively. CCS grading system performed better than the ASITN/SIR collateral score predicting 3-month mRS score and 24-h CED grading in stroke patients with favourable collaterals who received thrombectomy for MCA occlusion.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ASPECT score; Cerebral edema; Collateral Score; Infarct growth; Intracerebral hemorrhage; NIHSS score; Stroke; TICI score; Thrombectomy; mRS score

Mesh:

Year:  2022        PMID: 35982197     DOI: 10.1007/s11239-022-02692-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   5.221


  2 in total

1.  Favourable collaterals according to the Careggi Collateral Score grading system in patients treated with thrombectomy for stroke with middle cerebral artery occlusion.

Authors:  Giulia Sajeva; Raffaele Augelli; Manuel Cappellari; Cecilia Zivelonghi; Mauro Plebani; Nicolò Mandruzzato; Salvatore Mangiafico
Journal:  J Thromb Thrombolysis       Date:  2022-08-18       Impact factor: 5.221

2.  Semi-quantitative and qualitative evaluation of pial leptomeningeal collateral circulation in acute ischemic stroke of the anterior circulation: the Careggi Collateral Score.

Authors:  Salvatore Mangiafico; Arturo Consoli; Leonardo Renieri; Andrea Rosi; Alioscia De Renzis; Chiara Vignoli; Leonardo Capaccioli
Journal:  Ital J Anat Embryol       Date:  2013
  2 in total
  1 in total

1.  Favourable collaterals according to the Careggi Collateral Score grading system in patients treated with thrombectomy for stroke with middle cerebral artery occlusion.

Authors:  Giulia Sajeva; Raffaele Augelli; Manuel Cappellari; Cecilia Zivelonghi; Mauro Plebani; Nicolò Mandruzzato; Salvatore Mangiafico
Journal:  J Thromb Thrombolysis       Date:  2022-08-18       Impact factor: 5.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.